- Home
- LGCY vs LPTX Comparison
LGCY vs LPTX Comparison
Compare LGCY & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- LPTX
- Stock Information
- Founded
- LGCY 2009
- LPTX 2011
- Country
- LGCY United States
- LPTX United States
- Employees
- LGCY N/A
- LPTX N/A
- Industry
- LGCY
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LGCY
- LPTX Health Care
- Exchange
- LGCY NYSE
- LPTX Nasdaq
- Market Cap
- LGCY 117.7M
- LPTX 119.6M
- IPO Year
- LGCY 2024
- LPTX N/A
- Fundamental
- Price
- LGCY $11.05
- LPTX $0.38
- Analyst Decision
- LGCY Strong Buy
- LPTX Buy
- Analyst Count
- LGCY 2
- LPTX 2
- Target Price
- LGCY $10.65
- LPTX $8.00
- AVG Volume (30 Days)
- LGCY 67.7K
- LPTX 317.5K
- Earning Date
- LGCY 05-15-2025
- LPTX 08-11-2025
- Dividend Yield
- LGCY N/A
- LPTX N/A
- EPS Growth
- LGCY 21.53
- LPTX N/A
- EPS
- LGCY 0.62
- LPTX N/A
- Revenue
- LGCY $58,970,210.00
- LPTX N/A
- Revenue This Year
- LGCY $33.77
- LPTX N/A
- Revenue Next Year
- LGCY $24.88
- LPTX N/A
- P/E Ratio
- LGCY $17.67
- LPTX N/A
- Revenue Growth
- LGCY 37.92
- LPTX N/A
- 52 Week Low
- LGCY $3.60
- LPTX $0.22
- 52 Week High
- LGCY $11.20
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- LPTX 46.09
- Support Level
- LGCY N/A
- LPTX $0.38
- Resistance Level
- LGCY N/A
- LPTX $0.44
- Average True Range (ATR)
- LGCY 0.00
- LPTX 0.04
- MACD
- LGCY 0.00
- LPTX -0.00
- Stochastic Oscillator
- LGCY 0.00
- LPTX 22.52
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .